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microRNA-222 Controls Neovascularization by Regulating
Signal Transducer and Activator of Transcription
5A Expression
Patrizia Dentelli, Arturo Rosso, Francesca Orso, Cristina Olgasi, Daniela Taverna, Maria Felice Brizzi
Objective—Inflammatory stimuli released into atherosclerotic plaque microenvironment regulate vessel formation by
modulating gene expression and translation. microRNAs are a class of short noncoding RNAs, acting as
posttranscriptional regulators of protein-coding genes involved in various biological processes, including vascular
cell biology. Among them, microRNA-221/222 (miR-221/222) seem to negatively modulate vascular remodeling
by targeting different target genes. Here, we investigated their potential contribution to inflammation-mediated
neovessel formation.
Methods and Results—We used quantitative real-time RT-PCR amplification to analyze expression of 7 microRNAs
previously linked to vascular biology, such as miR-17-5p, miR-21, miR-126, miR-210, miR-221, miR-222, and
miR-296 and found high levels of expression for all of them in quiescent endothelial cells. However, miR-126, miR-221,
miR-222, and miR-296 turned out to be down-modulated in endothelial cells exposed to inflammatory stimuli. Applying
a gain-of-function approach, we demonstrated that, among them, only miR-222 was involved in inflammation-mediated
vascular remodeling. In addition, we identified signal transducer and activator of transcription 5A (STAT5A) as a bona
fide target of miR-222 and observed that miR-222 negatively correlated with STAT5A expression in human endothelial
cells from advanced neovascularized atherosclerotic lesions.
Conclusion—We identified STAT5A as a novel miR-222 target, and this finding opens up new perspectives for treatment
of vascular diseases. (Arterioscler Thromb Vasc Biol. 2010;30:1562-1568.)
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Inflammation represents a critical and unifying drivingforce promoting atherosclerotic plaque progression. Mac-
rophages and T lymphocytes modulate lesion growth, by
releasing cytokines and growth factors, as suggested by the in
vivo angiogenic properties of some of these secreted factors.1
Early studies demonstrated that T cells infiltrating the ath-
erosclerotic plaque release interleukin (IL)-31–3 and basic
fibroblast growth factor (bFGF), both promoting in vivo new
vessel formation.3,4 These observations sustain the possibility
that, in concert with bFGF or with other soluble factors, IL-3
may contribute to plaque progression. Moreover, as recently
demonstrated, like IL-3,4 bFGF induces vascular endothelial
morphogenesis by activating the signal transducer and acti-
vator of transcription (STAT)5A signaling pathway.5 The
STAT5 transcription factors migrate into the nucleus and
regulate the expression of genes involved in different cell
functions, including cell proliferation and cell migration.6 In
particular, despite their high degree of conservation, several
lines of evidence indicate that the 2 homologous proteins,
STAT5A and STAT5B, exert nonredundant functions in the
cardiovascular system.7–9
See accompanying article on page 1500
New vessel formation is controlled by a complex net-
work of genes. microRNAs (miRNAs) have recently come
into focus as powerful players that control gene expression
posttranscriptionally.10 –13 miRNAs are short noncoding
RNAs that negatively regulate gene expression, acting on
their target mRNAs, in a tissue- and cell type-specific
manner.10 miRNA profiles on endothelial cells (ECs)
revealed the presence of specific miRNAs, such as
miRNA-17-5p (miR-17-5p), miR-21, miR-126, miR-210,
miR-221/222, and miR-296, involved in the regulation of
angiogenesis.10 –13 In particular, the miR-221/miR-222
family seems to negatively modulate angiogenesis by
targeting the c-Kit receptor.14 More recently, p27Kip1 and
p57Kip2 have also been identified as target genes involved
in miR-221/miR-222-induced smooth muscle cell (SMC)
proliferation.15
The present study aimed to investigate the contribution of
miR-221/222 in inflammation-mediated neoangiogenesis and
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their potential involvement in atherosclerotic intraplaque
neovascularization.
Materials and Methods
Cell Cultures and Cell Proliferation Assay
ECs were isolated from a human umbilical vein and cultured as
previously described.4 To perform the experiments, ECs were
synchronized to quiescent state by serum starvation for 12 hours
(overnight), then the cells were cultured in the presence of 1%
bovine calf serum, untreated or treated for 24 hours to 48 to 72 hours
with IL-3 (20 ng/mL) or with bFGF (10 ng/mL). Cell viability was
evaluated by trypan blue at the end of each experiment, and
proliferative activity was assayed by direct cell count, by 3 individ-
ual operators in triplicate, as previously described.1 Proliferation was
evaluated by time-course experiments (24, 48, and 72 hours).
Forty-eight hours of IL-3 and bFGF stimulation was used throughout
the study. In selected experiments, untreated, bFGF-treated (data not
shown), or IL-3-treated ECs were transiently transfected with pre-
miR negative control, pre-miR-125a-3p, pre-miR-222, pre-miR-221,
or pre-miR-126 precursor oligonucleotides or alternatively with
anti-miR negative control, anti-miR-221, or anti-miR-222 inhibitor
oligonucleotides (Applied Biosystems), according to manufacturer’s
recommendation, and analyzed 48 hours later.
RNA Isolation and Quantitative Real-Time PCR
(qRT-PCR) for miRNAs Expression
Total RNA was isolated using TRIzol Reagent (Invitrogen) from
untreated or treated cells, as indicated, and from human arterial
samples- or Matrigel plug-derived ECs, following manufacturer’s
instructions. The expression of miR-17-5p, miR-21, miR-125a-3p,
miR-126, miR-210, miR-221, miR-222, and miR-296 in different
experimental conditions was evaluated using the TaqMan miRNA
assay kit (Applied Biosystems). Single-stranded cDNA was synthe-
sized from 50 ng of total RNA using looped primers of the TaqMan
miRNA assay and TaqMan miRNA reverse transcription kit (Ap-
plied Biosystems). Each cDNA generated was amplified by qRT-
PCR using sequence-specific primers from TaqMan miRNA assay in
the ABI PRISM 7700 Sequence detection system (Applied Biosys-
tems). miRNA expression was normalized to small nuclear RNA,
RNU6B.
Reagents and antibodies, EC migration assay, qRT-PCR for
STAT5A expression, Northern blot analysis, Western blot analysis,
luciferase miRNA target reporter assay, endogenous depletion of
STAT5A by small interfering RNAs, in vivo experiments, immuno-
fluorescence analysis, isolation of ECs from Matrigel plugs, human
arterial samples and isolation of vascular cells, statistical analysis,
and an extended version of cell cultures and cell proliferation assay
were described in detail in the supplemental section, which is
available online at http://atvb.ahajournals.org.
Results
miRNA Expression in ECs Exposed to
Inflammatory Stimuli
T cell-derived cytokine IL-3, like bFGF,1,2 acts as an inflam-
matory angiogenic mediator.3,4 To evaluate the biological
functions of miRNAs in inflammatory angiogenesis, a subset
of 7 miRNAs, previously known to be involved in angiogen-
esis,10–13 was investigated by qRT-PCR. To this end, ECs
were exposed or not (quiescent) to IL-3 or bFGF (Figure 1A).
Consistent with previous reports, high expression of miR-17-
5p, miR-21, miR-126, miR-210, miR-221, miR-222, and
miR-296 was found in quiescent ECs, whereas a significant
down-regulation of miR-296, miR-126, and miR-221/222
was detected in ECs challenged with both IL-3 and bFGF. No
change in miR-17-5p, miR-21, and miR-210 expression was
observed either after IL-3 and bFGF stimulation (Figure 1A).
Further validation of some of them was obtained by Northern
blot analysis (supplemental Figure I), thus suggesting that
angiogenic inflammatory stimuli might share a common
miRNA signature (Figure 1A). To verify the biological
relevance of miR-126, miR-296, and miR-221/222, func-
tional studies were performed in ECs using a gain-of-function
approach (Figure 1B). As reported in Figure 1C, ECs over-
expressing pre-miR-222, but not pre-miR-221, pre-miR-126,
or pre-miR-296 (data not shown), failed to undergo prolifer-
ation and to migrate in response to IL-3, compared with
negative controls. Similar results were obtained on bFGF
stimulation as well (data not shown), suggesting that miR-222
is specifically controlling vascular growth.
STAT5A Is a Novel miR-222 Target in ECs
Challenged With IL-3 and bFGF
bFGF and IL-3 trigger vascular EC morphogenesis by acti-
vating the STAT5 signaling pathway.5 According to various
prediction software (miRBase-MicroCosm version v5 and
miRecords), STAT5A is a predicted miR-222 and miR-221
target (Figure 2A). Thus, biochemical studies were performed
Figure 1. miRNA expression in ECs exposed to inflammatory
stimuli. A, Expression of miR-17-5p, miR-21, miR-126, miR-210,
miR-221, miR-222, and miR-296 in quiescent or bFGF- or IL-3-
treated ECs was analyzed by single assay qRT-PCR. The
reported data were normalized to RNU6B. B, qRT-PCR was
performed on IL-3-challenged ECs 48 hours after transfection of
pre-miR negative control (neg c), pre-miR-126, pre-miR-221, or
pre-miR-222 precursors. Fold expression of miRNAs was repre-
sentative of 3 independent experiments performed in triplicate.
C, Cell proliferation (upper) and cell migration (lower) assays
were performed as described in Materials and Methods in ECs
transfected as above in the presence of IL-3 (*P0.05 and
**P0.01, experimental versus control values).
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using a gain-of-function approach (Figure 1B). As shown in
Figure 2B, despite the fact that STAT5A was also a predicted
target of miR-221, miR-222, but not miR-221, overexpres-
sion was associated with down-regulation of STAT5A pro-
tein levels and, consistently with the biological relevance of
this correlation, overexpressing STAT5A, lacking the endog-
enous 3-untranslated region (UTR), rescued cyclin D1 ex-
pression (Figure 2C) and EC functions, such as proliferation
and migration (Figure 2D). No effect of miR-126 was
observed on STAT5A in our system (Figure 2B). To validate
our data, biochemical and functional studies using a loss-of-
function approach were performed (supplemental Figure II).
As shown in supplemental Figure IIB through IID, a further
increment in STAT5A expression was detected by expressing
anti-miR-222 but not anti-miR-221 (supplemental Figure
IIA). Consistently, both cell proliferation or cell migration
(supplemental Figure IIC) were further improved in the
presence of IL-3. However, even in the presence of slightly
increased expression of STAT5A, no biological effect was
observed following anti-miR-222 transfection in absence of
IL-3, possibly because the anti-miR cannot decrease miR-222
levels to rescue IL-3 effect. Similar results were obtained
when the experiments were performed in the presence of
bFGF (data not shown). Finally, by knocking down STAT5A
expression in ECs (supplemental Figure III), by RNA inter-
ference, we were able to reproduce miR-222 biological
effects. To validate these data, STAT5A and miR-222 ex-
pression was evaluated in quiescent ECs following bFGF or
IL-3 stimulation. Increased STAT5A protein, but not mRNA
levels (Figure 3A, left, and supplemental Figure IVA), and
decreased miR-222 (Figure 3A, right) expression were de-
tected. In parallel, increased cyclin D1 protein levels (Figure
3A) and cell proliferation, as well as cell migration (Figure
3B), were observed. No change in c-Kit and p27Kip1 were
observed (Figure 3A and supplemental Figure IVB). To
ascertain the direct effect of miR-222 on STAT5A-3-UTR,
the luciferase reporter vectors containing the wild-type full-
length STAT5A- or STAT5B-3-UTR were transfected in
ECs. An increased luciferase activity was detected in
STAT5A-3-UTR expressing ECs exposed to both bFGF or
IL-3 (Figure 3C). Decreased gene reporter activity was
observed when the same wild-type construct was transfected
in HEK293 cells (an easily transfectable miR-222 empty
recipient) and when overexpression of miR-222 was forced
(supplemental Figure V). However, increased luciferase ac-
tivity was observed when the same HEK293 cells were
transfected with a construct carrying a mutant STAT5A-3-
UTR following miR-222 overexpression (supplemental Fig-
ure VB). Nevertheless, pre-miR-221 and pre-miR-222 were
able to act on their specific targets. Indeed, when HEK293
cells were transfected with constructs carrying p27kip1-3-
UTR or c-Kit-3-UTR and overexpressing pre-miR-221 or
pre-miR-222, a decreased luciferase activity was detected
(supplemental Figure VC). STAT5A is also a predicted
miR-125a-3p target (see the prediction software above). As
shown in supplemental Figure VIA, miR-125a-3p was down-
regulated by inflammatory stimuli. However, we failed to
detect changes in STAT5A or cyclin D1 protein expression
and in luciferase activity following IL-3 treatment in miR-
125a-3p-overexpressing cells (supplemental Figure VIB and
VIC), further indicating that STAT5A is mostly regulated by
miR-222 during inflammation-mediated neoangiogenesis.
Together, these findings led us to focus our in vivo investi-
gations on miR-222.
miR-222 Controls In Vivo Neoangiogenesis
and Intraplaque Vessel Formation by
Targeting STAT5A
The role of miR-222 in regulating vessel growth was evalu-
ated in vivo by injecting severe combined immunodeficient
mice with Matrigel plugs containing bFGF or IL-3 and ECs
overexpressing miR-222 or its negative control. As shown in
Figure 4A, human CD31-positive ECs, but no functional
Figure 2. STAT5A is regulated by miR-
222. A, Alignment of miR-222 with its
potential binding site in the 3-UTR of
STAT5A mRNA. B, IL-3-cultured ECs
transfected with pre-miR negative con-
trol (neg c), pre-miR-126, pre-miR-221,
or pre-miR-222 precursors were lysed
and analyzed by Western blot for
STAT5A, STAT5B, cyclin D1, p27Kip-1,
and -actin expression. C, ECs cultured
with IL-3 were transfected with pre-miR
negative control (neg c) or pre-miR-222,
only or in combination with a STAT5A
expression vector (5A). 48 hours later,
cell extracts were prepared and sub-
jected to SDS-PAGE, and the filters
were immunoblotted (IB) with the indi-
cated antibodies. D, Cell proliferation
(upper) and cell migration (lower) assays
were performed in ECs treated as
described in C (for B, C, and D,
*P0.05, experimental versus control
values).
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vessels (no tubular structures containing erythrocytes into the
lumen), were detected in Matrigel plugs injected with miR-
222-overexpressing cells, compared with negative controls
(Figure 4A). Consistently, biochemical analysis on ECs from
the same Matrigel plugs revealed almost undetectable levels
of STAT5A protein (Figure 4B). Once more, we did not
detect any change in c-Kit or p27Kip1 expression following
miR-222 overexpression (Figure 4B). In addition, the finding
that ECs, depleted of endogenous STAT5A by RNA inter-
ference, injected in severe combined immunodeficient mice
replicated miR-222 overexpressing phenotype further sus-
tains the above data (supplemental Figure VII). Conversely, a
rescue of angiogenesis followed STAT5A exogenous expres-
sion in miR-222-overexpressing ECs (Figure 4A). Instead,
reduced proliferation was observed in plugs injected with
miR-222-overexpressing ECs, as measured by Ki67 immu-
nostaining (supplemental Figure VIII).
Inflammatory cells stringently control intraplaque neovas-
cularization and lesion progression.1,2 IL-3, like bFGF, is
released in neointima microenvironment.3 Thus, the biologi-
cal relevance of miR-222 in regulating plaque progression
was investigated by isolating human ECs from normal and
atherosclerotic samples. As already reported,14,15 miR-222 is
highly expressed in CD31-positive ECs recovered from
normal vessels (Figure 5A). Conversely, from early to ad-
vanced lesions, a progressively decreased expression of
miR-222, but not of miR-17-5p, was detected (Figure 5A; for
atherosclerotic lesion description, please see supplemental
material). Tissue-specificity of miR-222 expression is pro-
vided by the following observations: (1) no anti--smooth
muscle actin staining was revealed in the recovered ECs from
advanced lesions, (2) no changes in miR-222 expression
could be detected in SMCs exposed to IL-3 or bFGF, and (3)
the level of miR-222 was almost undetectable in unstimulated
or macrophage colony stimulating factor-stimulated periph-
eral blood mononuclear cells (Figure 5B). Similar results
were obtained by lipopolysaccharide stimulation (data not
shown). The possibility that miR-222 expression might neg-
atively control neovascularization is sustained by the prolif-
eration rate of ECs lining vessels inside the advanced lesions
(positive immunostaining for Ki67) (Figure 5C) and by the
increased number of vessels in low miR-222 expressing
plaques (Figure 5D).
ECs recovered from normal vessels and from lesions at
different stages of progression were also evaluated for
STAT5A expression. Indeed, STAT5A is barely detectable in
nonproliferating normal vessel, and its expression increases
from early (Figure 5A, lane 1) to advanced lesions (Figure
5A, lanes 2 and 3). A positive STAT5A immunostaining was
also detected in vessels from advanced lesions compared with
normal tissues (supplemental Figure IX). Moreover, the
finding that no changes in c-Kit and p27Kip1 protein expres-
sion could be detected (Figure 5A) again identifies STAT5A
as the main regulator of neovascularization, which is mostly
regulated posttranscriptionally by miR-222.
Discussion
Atherosclerotic lesion progression requires intraplaque neo-
vascularization,1,2 and the inflammatory cells contained in the
neointima mainly contribute to this process by releasing
cytokines and growth factors, such as IL-3 and bFGF.1–3
Although these mediators are known to control a number of
different genes, very little is known about their effects in
regulating gene expression and translation during vessel
formation. Recently, miRNAs have been recognized as neg-
ative regulators of gene expression.10–12 Key targets of
Figure 3. STAT5A is a direct target of miR-222 in ECs treated
with IL-3 or bFGF. A, Quiescent or bFGF- or IL-3-stimulated
ECs were used to perform qRT-PCR for miR-222 expression
(right) and Western blot analysis (left) for c-Kit, STAT5A,
STAT5B, p27Kip-1, p57Kip2, cyclin D1, and -actin expression as
indicated (left). Fold expression of miRNAs was representative
of 3 independent experiments performed in triplicate. B, Prolifer-
ation (right) and migration (left) assays of ECs treated as above.
C, pmiR vector or pmiR-3-UTR STAT5A or pmiR-3-UTR
STAT5B luciferase constructs were transfected into quiescent or
IL-3- or bFGF-treated ECs. The relative luciferase activity is
reported (*P0.05, experimental versus control values).
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miRNAs have been identified in cancer cells,13,16,17 but
relatively little is known about miRNAs involved in vascular
diseases. So far, only a few specific miRNAs recognized as
proangiogenic or antiangiogenic miRNAs have been de-
scribed.10–13 Among the latter, miR-221/miR-222 have been
reported to negatively regulate vessel formation, by targeting
c-Kit.14 In addition, miR-221/miR-222 have been shown to
act as crucial modulators of SMC proliferation by targeting
p27Kip1 and p57Kip2.15 However, the impact of hypoxia,
inflammation, cardiovascular risk factors, or laminar sheer
stress on the expression profile of miRNAs in vascular cell
biology is still under investigation.18–20 Indeed, very recent
data demonstrated that in pathological settings, linked to
inflammation, growth factors, or cytokines, can differentially
regulate miRNA expression in ECs.21,22 In the present study,
we provide evidence that miR-222 is the main regulator of
vascular cell biology in an inflammatory microenvironment
containing IL-3 or bFGF. Moreover, we identify STAT5A as
a novel miR-222 target involved in inflammation-mediated
neovessel formation.
The 2 highly homologous proteins, STAT5A and
STAT5B, act as signaling components between the plasma
membrane and the nucleus and as transcriptional factors by
regulating the expression of genes involved in proliferation,
survival, and differentiation.6 STAT5A and STAT5B show a
high degree of conservation. However, these 2 homologous
proteins exert nonredundant functions during developmental
processes and in the adult cardiovascular system.7 For in-
stance, STAT5B, unlike STAT5A, seems to play a role in
balloon injury-induced neointima formation8 and to regulate
gene expression in diabetes-associated vascular disease.9
Conversely, STAT5A seems to be involved in postmyocar-
dial infarction remodeling.23 We found that during vessel
growth, STAT5A, but not STAT5B, is posttranscriptionally
regulated by miR-222, therefore defining an additional non-
redundant function for STAT5 proteins.
Despite the fact that miR-222 and miR-221 contain the
same seed and that the expression of both miRNAs was
reduced in ECs following IL-3 or bFGF treatment, miR-221
did not appear to be biologically relevant for inflammation-
mediated vascular growth (ie, proliferation, migration,
STAT5A and cyclin D1 expression, and STAT5A binding
3-UTR). Different biological activities between miR-221
and miR-222 were previously observed in a model of liver
tumorigenesis, in which miR-221, but not miR-222, was able
to accelerate tumors in mice.24 One can make the hypothesis
that specific miRNAs activities between miR-221 and miR-
222 depend on sequence differences present downstream of
the common seed in the 2 miRNAs. In fact, it has been
predicted and/or demonstrated that other nucleotides, apart
from the seed sequence, can be relevant for miRNA activity
as discussed in Filipowicz et al,25 Bartel,26 and else-
where.27–29 However, functional evaluation of each specific
nucleotide downstream of the seed can be performed only by
a complete mutagenesis analysis.
miR-222 was shown to be down-modulated in endometri-
oid and clear cell ovarian carcinomas but not in the serous
type of the same tumor.30 These results indicate that miRNA
Figure 4. miR-222 controls in vivo
neoangiogenesis by targeting
STAT5A. A, Matrigel plug sec-
tions, containing IL-3 or bFGF and
ECs transfected with pre-miR
negative control (neg c) or pre-
miR-222 oligonucleotide, only or
in combination with a STAT5A
expression vector (5A), were
recovered 4 days after implanta-
tion in severe combined immuno-
deficient mice. Histological (mag-
nification 10; left) and
immunofluorescence (magnifica-
tion 20; right) analyses are
reported. Immunofluorescence
stains were performed with an
anti-human CD31 antibody (green)
and the 4,6-diamidino-2-
phenylindole DAPI nuclear marker
(blue). Quantification of neoformed
vessels observed in histological
analysis was expressed as
percentageSD of the vessel area
to the total Matrigel area. Scale
bars indicate 200 m for histolog-
ical analysis and 50 m for immu-
nofluorescence analysis. B, ECs,
recovered by CD31-positive mag-
netic sorting from the Matrigel
plugs described above, were ana-
lyzed by qRT-PCR and Western
blotting for miR-222 and for c-Kit,
STAT5A, p27Kip1, vascular endo-
thelial-cadherin (VE-cadherin), -smooth muscle actin (SMA), and -actin expression, respectively. Fold expression of miRNAs was rep-
resentative of 3 independent experiments performed in triplicate (*P0.05, experimental versus control values).
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activity can be very dependent on the cellular environment
and that miRNA-mediated control can display specificity in
terms of functional restriction to a particular cellular context
or differentiation pathway.31,32 Probably, this could be the
reason why we were not able to see an effect of miR-222 on
c-Kit in our experimental conditions. Moreover, the fact that
we did not observe modulations of miR-222 on p27Kip1, even
if this is a validated miR-222 target, with a proven role in
SMC proliferation and cell cycle,15 sustains the possibility
that miR-222 effects and/or its targets are cell type dependent.
Figure 5. miR-222 correlates with STAT5A expression during lesion progression in humans. A, ECs, recovered from representative ath-
erosclerotic plaque samples (see Materials and Methods), by CD31-positive magnetic sorting, were analyzed for the expression of miR-
222 and miR-17-5p (left) or the indicated proteins (right) by qRT-PCR or Western blotting, respectively (N.V.: normal vessel, from 1 to 3
progressively more advanced atherosclerotic lesions, ie, 1: early lesion, 2: fibromuscolar plaques, and 3: advanced lesions). IL-3-treated
ECs or SMCs [for -smooth muscle actin (SMA) expression] were used as positive controls (). VE-cadherin, vascular endothelial-
cadherin. B, miR-222 expression was evaluated by qRT-PCR on peripheral blood mononuclear cells (PB-MNCs), untreated or treated
with macrophage colony stimulating factor (M-CSF), or on SMCs, subjected or not to IL-3 or bFGF treatment. Quiescent ECs were
used as internal control (*P0.05, experimental versus control values). Fold expression of miRNAs was representative of 3 independent
experiments performed in triplicate. C, Representative immunofluorescence staining of advanced lesions. Anti-human CD31 (green) or
Ki67 (red) antibodies were used in association with the nuclear marker [4,6-diamidino-2-phenylindole (DAPI)] (magnification 40). Scale
bars indicate 20 m. D, Intraplaque vessel number was evaluated by manual counting of CD31 positive vessels by 3 individual opera-
tors and reported as numberSD of vessels per field (magnification 20) (*P0.05, experimental versus control values).
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Understanding the complex network of miRNAs and their
targets may provide new tools to develop therapeutic strate-
gies, not only to enhance neovascularization of ischemic
tissues, but also to hamper pathological vessel growth.
Indeed, in conditions such as atherosclerosis, intimal angio-
genesis occurs as part of the adaptive changes known as
vasculature remodeling.1,2 Our finding demonstrating that
miR-222 acts as an antiangiogenic miRNA, by controlling
STAT5A expression, provides promising perspectives to
interfere with deregulated vascular remodeling and athero-
sclerotic disease progression.
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SUPPLEMENTAL MATERIAL 
MATERIALS AND METHODS 
Reagents and Antibodies. M199 medium (endotoxin-tested), RPMI medium, MEM-D-Val medium 
bovine serum albumin (BSA), bovine calf serum (BCS), Hank’s Buffered Salt Solution (HBSS) and 
collagenase I were from Sigma-Aldrich (St Louis, MO, USA). Bovine calf serum (BCS) 
(endotoxin-tested) was from HyClone (Logan, UT, USA). Trypsin was purchased from Difco 
(Detroit, MI, USA). Nitrocellulose filters, HRP-conjugated anti-rabbit IgG and anti-mouse IgG, 
molecular weight markers, chemiluminescence reagent (ECL) were from Amersham 
(Braunschweig, Germany). The presence of endotoxin contamination was tested by the Limulus 
amebocyte assay (concentration was <0.1 ng/ml). Human Interleukin-3 (IL-3) was a gift from 
Sandoz Pharma Ltd (Basel, Switzerland). Human basic Fibroblast Growth Factor (bFGF), human 
Macrophage-Colony Stimulating Factor (M-CSF) and LPS were from Invitrogen.  
Anti-β-actin, anti-STAT5A (L-20), anti-STAT5B (G-2), anti-p27
Kip1
, anti-p57
 Kip2
, anti-c-Kit and 
anti-cyclin D1 antisera were obtained from Santa Cruz Biotechnology, Inc.,
 
Heidelberg, Germany. 
Anti-VE-cadherin, anti-αSMA, anti-human CD31-FITC and secondary FITC- or TRITC-
conjugated antibodies were from Sigma-Aldrich. Anti-Ki67 antibody was from Dako (Glostrup, 
Denmark).  
Cell Cultures and Cell Proliferation assay. Endothelial cells (ECs) were isolated from human 
umbilical vein within 4 h from delivery by Trypsin treatment (0.1%), cultured in M199 medium 
with the addition of 20% BCS and 5 ng/ml of bFGF and used at early passages (II-III). To perform 
the experiments ECs were synchronized to quiescent state by serum starvation for 12 h (overnight) 
then the cells were cultured in the presence of 1% BCS, untreated or treated for 24-48-72 h with IL-
3 (20 ng/ml) or with bFGF (10 ng/ml). Cell viability was evaluated by trypan blue at the end of each 
experiment and proliferative activity was assayed by direct cell count,
 
by three individual operators 
in triplicate, as previously described 
1
. Proliferation was evaluated by time course experiments (24, 
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48 and 72 h). 48 h of IL-3 and bFGF stimulation was used throughout the study. In selected 
experiments bFGF-treated (data not shown) or IL-3-treated or untreated ECs were transiently 
transfected with pre-miR negative control, pre-miR-125a-3p, pre-miR-222, pre-miR-221 or pre-
miR-126 precursor oligonucleotides or alternatively with anti-miR negative control, anti-miR-221 
or anti-miR-222 inhibitor oligonucleotides (Applied Biosystem, Foxter Cyto, CA), according to 
manufacturer’s recommendation and analyzed 48 h later. Where indicated pre-miR-222 precursor 
was transiently co-transfected with a STAT5A expression vector 
2
, using the lipofectin method 
(Invitrogen), according to the vendor's instructions. Human vascular smooth muscle cells (SMCs) 
were isolated from the umbilical cord within 4 h from delivery. The vascular SMC layer was 
identified and characterized as described 
3
. SMCs were cultured in MEM-D-Val medium plus 10% 
BCS and used at early passages (II-IV). Serum-starved SMCs were untreated or treated for 48 h 
with IL-3 (20 ng/ml) or bFGF (10 ng/ml) to evaluate miR-221/222 expression by qRT-PCR. 
HEK293 human epithelial cells (American Type Culture Collection) were cultured in RPMI 
medium supplemented with 10% BCS. In selected experiments HEK293 cells were transiently 
transfected with pre-miR negative control, pre-miR-222 or pre-miR-221 precursor oligonucleotides 
(Applied Biosystem, Foxter Cyto, CA) according to manufacturer’s recommendation and analyzed 
48 h later. Peripheral-blood mononuclear cells (PB-MNCs) were isolated by Ficoll Histopaque
 
1077 
(Sigma-Aldrich, St Louis, MO) from blood donors subjects and used directly or upon 7 days of M-
CSF (1000 U/ml) or 24 h of LPS (100ng/ml) stimulation to evaluate miR-221/222 expression by 
qRT-PCR. The institutional review board of the hospital
 
approved the study. 
EC migration assay. Migration of ECs was performed in Boyden’s chambers, as previously 
described 
4
. Quiescent ECs that passed across the filter (8-µm pore size) 4 h
 
after addition of bFGF 
(10 ng/ml) or IL-3 (20 ng/ml)
 
in the lower compartment of the chamber or kept in the vehicle alone
 
(saline containing 0.25% BSA), were counted.
 
Where indicated ECs were transfected for 48 h with 
pre-miR negative control, pre-miR-126, pre-miR-221, pre-miR-222 or pre-miR-222+STAT5A 
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expression vector or with anti-miR negative control, anti-miR-221 or anti-miR-222 inhibitor 
oligonucleotides or alternatively with scramble or STAT5A siRNAs and used 48 h later. 
RNA Isolation and Quantitative Real-time PCR (qRT-PCR) for miRNAs or STAT5A expression. 
Total RNA was isolated using TRIzol Reagent® (Invitrogen) from untreated or treated cells, as 
indicated, and from human arterial samples- or Matrigel plug-derived ECs, following 
manufacturer’s instructions. The expression of miR-17-5p, miR-21, miR-125a-3p, miR-126, miR-
210, miR-221, miR-222 and miR-296 in different experimental conditions was evaluated using the 
TaqMan microRNA assay kit (Applied Biosystems, Foxter Cyto, CA). Single-stranded cDNA was 
synthesized from 50 ng of total RNA using looped primers of the TaqMan microRNA assay and 
TaqMan microRNA reverse transcription kit (Applied Biosystems). Each cDNA generated was 
amplified by qRT-PCR using sequence-specific primers from TaqMan microRNA assay in the ABI 
PRISM 7700 Sequence detection system (Applied Biosystem). miRNA expression was normalized 
to small nuclear RNA, RNU6B. STAT5A mRNA quantification was also performed by qRT-PCR 
using specific Taq-Man Gene Expression assay (Applied Biosystem). GAPDH gene was used as 
standard reference. 
Northern Blot Analysis. Total RNA was isolated from ECs, treated as indicated, using TRIzol 
Reagent® (Invitrogen), following manufacturer’s instructions. Northern blot analysis was performed 
according to standard methods as previously described 
5
. Filters were hybridized to 
32
P random-
priming labeled DNA probes corresponding to human STAT5A and β-actin cDNAs, washed for 30 
minutes in 0.1XSSC and 1% SDS at 52°C and then exposed to X-ray film for 2-4 days.  
Validation of miR-126, miR-221 and miR-222 expression in untreated, or IL-3- or bFGF-treated 
ECs was obtained by Northern blot. Total RNA samples (25µg each) were subjected to 12.5% 
TBE/urea gel electrophoresis and transferred to a Hybond N+ membrane (Amersham). Membranes 
were hybridized (45 °C over-night) with hsa-miR-126, hsa-miR-221 or hsa-miR-222 5'-
digossigenin-labeled mercury LNA detection probes (Exiqon, Vedbaek, Denmark). U6 snRNA was 
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used as endogenous control. Hybridization buffer, wash buffer, blocking buffer and detection buffer 
were supplied by Roche (Basel, Switzerland). The results were visualized on X-ray film. 
Western Blot Analysis. Cells were lysed (50mM Tris HCl ph 8.3, 1% Triton X-100, 10 mM PMSF, 
100 U/ml aprotinin, 10 µM/ml leupeptin) and protein concentrations were obtained as previously 
described 
3,4
. 50 µg of proteins were subjected to SDS-PAGE, transferred into nitrocellulose 
membranes, blotted with the indicated antibodies and revealed by chemiluminescence detection 
system (ECL). 
Luciferase miRNA Target Reporter Assay. The luciferase reporter assay was performed using a 
construct generated by sub-cloning PCR products amplified from 3’UTR full-length of STAT5A, 
STAT5B, c-Kit and p27
Kip1
 mRNA in the SacI restriction site of the luciferase reporter vector pmiR 
(Ambion, Applied Biosystem). PCR products were obtained using the following primers:  
STAT5A: sense, 5’AAGAGCTCATGTTTGAATCCCACGCT3’; 
antisense,5’TTGAGCTCACACAAATGTGTGGTCTT3’; 
STAT5B:sense,5’AAGAGCTCTGACCCCGCGACCTCTCCAT3’; 
antisense,5’AAGAGCTCCCCTTCAGAGGAAGGCTTTA3’;  
c-Kit: sense,5’AAGAGCTCGCAGAATCAGTGTTTGGGTCA3’; 
antisense,5’TTGAGCTCCTTCAGAACTGTCAACAATTGG3’; 
p27
Kip1
: sense, 5’AGAGCTCCAGATACATCACTGC;  
antisense, 5’TGAGCTCTATACTTGGCTCAG3’.  
A site-directed mutagenesis of the 3’UTR STAT5A amplified PCR product was performed to 
obtain the mutated miR-222 binding site. The sequence was generated using the Quik-Change Site-
Direct Mutagenesis kit (Stratagene, La Jolla, CA, USA). The oligonucleotide sense, 
5’CAGACCTGGAAAGAGGATGCAGCAGCG3’, containing the desired mutation, was designed 
according to the manufacturer’s instructions (the mutated nucleotide is bold and italicized). The 
insert identities were verified by sequencing. The pmiR, pmiR-3’UTR STAT5A, pmiR-3’UTR 
STAT5B, pmiR-3’UTR c-Kit and pmiR-3’UTR p27
Kip1
 luciferase reporter vectors were transiently 
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co-transfected in ECs, treated as indicated, or in HEK293 cells at 10:1 molar ratio with the pRL 
vector, coding for the Renilla luciferase, used as internal control of the luciferase assay, by the 
lipofectin method (Invitrogen), according to the vendor's instructions. Luciferase activities were 
analyzed 48 h after transfection by Dual-Luciferase Report Assay System (Promega), according to 
vendor’s instructions, using a TD20/20 double injector luminometer (Turner Designs, Forlì, IT). 
The results are expressed as relative luciferase expression (%), calculated by normalizing the ratio 
of the firefly/renilla luminescences. Luciferase activities, using the pmiR reporter vectors, above 
described, or the pmiR-3’UTR STAT5A mutated construct (MUT) were also evaluated in ECs or in 
HEK293 cells 48 h after transfection of pre-miR negative control, pre-miR-221, pre-miR-222 or 
pre-miR-125a-3p precursor oligonucleotides or in ECs after transfection of anti-miR negative 
control, anti-miR-221 or anti-miR-222 inhibitor oligonucleotides, according to Ambion’s 
instructions.  
Endogenous depletion of STAT5A by Small Interfering RNAs (siRNAs). To obtain inactivation of 
endogenous STAT5A, IL-3-cultured ECs were transiently transfected with non specific (scramble) 
or STAT5A siRNAs purchased by Qiagen (Valencia, CA, USA). Transfection was performed 
according to the vendor's instructions. 48 h later whole cell extracts were prepared and processed 
for Western blot. STAT5A depleted ECs were also used to perform cell proliferation or migration 
assays. Cell viability was evaluated at the end of the experiments. 
In Vivo Experiments. For angiogenesis assay SCID mice (five mice for each experimental group) 
were
 
injected s.c. with growth
 
factor–reduced Matrigel containing IL-3 (50 ng/ml) or bFGF (50 
ng/ml) and 2 x 10
6 
ECs, previously transfected with pre-miR negative control or pre-miR-222 
precursors, alone or in combination with a STAT5A expression construct, or alternatively with non 
specific (scramble) or STAT5A siRNAs and processed as described 
4-6
. Briefly, four days after 
injection Matrigel plugs were recovered and fixed in 10% buffered formalin and embedded in 
paraffin for histological and immunofluorescence analysis or digested for EC isolation. The vessel 
area and the total Matrigel area were planimetrically assessed from hematoxilin-eosin stained 
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sections as previously described 
4-6
. Only the structures possessing a patent lumen and containing 
RBC were considered vessels. Angiogenesis was expressed as the percentage±SD of the vessel area 
to the total Matrigel area (% vessel area, 10X magnification). Quantification of neo-formed vessels 
was also evaluated by CD31 staining of vascular ECs. Any stained EC or EC cluster, clearly 
separated from connettive tissue elements, was considered as a single microvessel and counted, 
according to Weidner et al. 
7
. Animal procedures conformed to
 
the Guide for Care and Use of 
Laboratory Resources (National Institutes
 
of Health publication no. 93-23, revised 1985). 
Immunofluorescence Analysis. Sections from paraffin-embedded blocks of Matrigel plugs, 
containing inflammatory stimuli and ECs, transfected with the indicated constructs, were collected 
onto poly-Lysine-coated slides and processed as previously described 
6
. For immunofluorescence 
assay, the samples were processed using anti-human CD31-FITC antibody and DAPI (Sigma-
Aldrich), as nuclear marker, or double stained with anti-human CD31-FITC, DAPI and anti-Ki67 
antibody, as proliferative marker. Human CD31 positive vessels were determined by counting 10 
randomly selected fields in three different samples (20X magnification). Sections from paraffin-
embedded samples of early and advanced lesions were double stained directly with anti-human 
CD31-FITC antibody and indirectly with anti-STAT5A and TRITC-conjugated secondary antibody 
(10X magnification). Samples of advanced lesion were also double stained with anti-human CD31-
FITC and anti-Ki67 antibodies.  Images were acquired with a Zeiss LSM 5 Pascal
 
confocal laser-
scanning microscope (Carl Zeiss, Jena, Germany)
 
equipped with a helium/neon laser (543 mm), an 
argon laser (450-530
 
mm), and an EC planar Neofluar 40x/1.3 oil-immersion DIC objective
 
lens. 
Images were analyzed using Zeiss LSM 5 version 3.2 software. 
Isolation of ECs from Matrigel Plugs. ECs were recovered from Matrigel plugs four days after 
injection into SCID mice. After digestion in HBSS containing 0.1% collagenase I for 30 min at 
37°C the cells were washed in medium plus 10% BCS and forced through a graded series of meshes 
to separate the cell component from Matrigel matrix. ECs were isolated via anti-human CD31 
antibody coupled to magnetic beads, by magnetic cell sorting using the MACS system (Miltenyi 
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Biotech Auburn, CA). Briefly, cells were labeled with the anti-human CD31 antibody for 20 min 
and then were washed twice and re-suspended in MACS buffer (PBS without Ca
2+
 and Mg
2+
, 
supplemented with 1% bovine serum albumin and 5 mmol/L EDTA) at the concentration of 0.5X 
10
6
 cells/80 µl. After washing, the cells were separated on a magnetic stainless steel wool column 
(Miltenyi Biotech, Auburn, CA) according to manufacturer’s recommendation. The endothelial 
phenotype of cells was verified by FACS analysis using an anti-vonWillebrand antibody (Sigma-
Aldrich: data not shown). The recovered cells were subjected to RNA isolation or lysed for Western 
Blot analysis. 
Human arterial samples and isolation of vascular cells. The approval was obtained from the 
Institutional Review Board of S. Giovanni Battista Hospital, Turin, Italy. Informed consent was 
provided according to the Declaration of Helsinki. Human non atherosclerotic and atherosclerotic 
arteries (renal and carotid arteries) were obtained from informed patients who underwent 
transplantation or endoarteriectomy. By histological analysis, we classified these into non-diseased 
(n=5), early lesion (n= 3), fibromuscolar plaques (n=4) and atheromatous plaques (n=5), indicated 
as advanced lesions, according to the American Heart Association histological criteria. 
Representative examples of early and advanced lesions were reported in Fig. S7. ECs lining the 
luminal side and intraplaque neo-formed vessels were double stained with anti-CD31-FITC 
antibody and anti-STAT5A antibody with TRITC-conjugated secondary antibody. Anti-mouse IgG 
antibody with anti-TRITC-conjugated secondary antibody were used as negative control. Neointima 
from fresh samples of advanced specimens or intima from non-atherosclerotic specimens were 
finely minced with scissors and digested by incubation for 1 hour at 37°C in HBSS containing 0.1% 
collagenase I. After washing in medium plus 10% BCS cell suspension was forced through a graded 
series of meshes to separate the cell component from stroma and aggregates. Cells were 
resuspended and ECs were isolated via anti-human CD31 antibody coupled to magnetic beads, by 
magnetic cell sorting using the MACS system (Miltenyi Biotech), as above described. Anti-
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vonWillebrand antibody was used to verify the endothelial phenotype (data not shown). The 
recovered cells were used for qRT-PCR and for Western Blot analysis. 
Statistical Analysis. All in vitro and in vivo results are representative of at least three independent 
experiments. The in vitro experiments were performed in triplicate. Densitometric analysis using a 
Bio-Rad GS 250 molecular imager was used to calculate the differences in the fold induction of 
protein expression (*p< 0.05 or **p<0.01, statistically significant between experimental and control 
values) and each Western blot panel and relative densitometric histogram reported in the figures 
were representative of the results obtained in triplicate. Significance of differences between 
experimental and control values was calculated using analysis of variance with Newman-Keuls 
multicomparison test. Similar statistical analysis was performed in the in vivo experiments. 
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Supplemental Figure I 
 
 
 
Supplemental Figure I. miRNA expression in ECs exposed to inflammatory stimuli. 
Expression of miR-126, miR-221 and miR-222 in quiescent or bFGF- or IL-3-treated ECs was 
validated by Northern blot analysis. The reported data were normalized to U6. (*p<0.05; 
experimental vs control values). 
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Supplemental Figure II 
 
Supplemental Figure II. miR-222 down-regulation further increases EC proliferation and 
migration only in the presence of IL-3. (A) Expression of miR-221 and miR-222 was analyzed by 
qRT-PCR on ECs, in the presence or in the absence of IL-3, 48 h after transfection of anti-miR 
negative control (neg c), anti-miR-221 or anti-miR-222 oligonucleotides. Fold expression of 
miRNAs was representative of three independent experiments performed in triplicate. (B) Untreated 
or IL-3-cultured ECs transfected with antagonist oligonucleotides, as above, were lysed and 
analyzed by Western Blot for STAT5A, STAT5B, cyclin D1, p27 Kip-1 and β-actin expression. (C) 
Cell proliferation (upper panel) and cell migration (lower panel) assays were performed in ECs 
treated as described in B. (D) pmiR vector or pmiR-3’UTR STAT5A or pmiR-3’UTR STAT5B 
luciferase constructs were transfected into ECs treated as above. The relative luciferase activity is 
reported. (*p < 0.05, experimental vs control values). 
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Supplemental Figure III 
 
 
 
Supplemental Figure III. STAT5A depletion phenocopies miR-222 over-expression. (A) ECs 
were transfected with STAT5A or scrambled sequence (scramble) siRNAs, cultured with IL-3 and 
lysed. The filters were immunoblotted with anti-STAT5A or anti-β-actin antibodies. (B) IL-3-
cultured ECs transfected with STAT5A or scramble siRNAs were analyzed for cell proliferation 
(upper panel) or cell migration (lower panel) assays. (*p<0.05, experimental vs control values). 
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 Supplemental Figure IV. 
 
 
 
Supplemental Figure IV. miR-222 does not affect STAT5A mRNA level and c-Kit or p27 
Kip-1
 
luciferase activity (A) qRT-PCR and Northern blot analysis were performed on quiescent or 
bFGFor IL-3-stimulated ECs to evaluate STAT5A expression. Data were normalized to GAPDH or 
β- actin expression, respectively. Fold expression of STAT5A was representative of three 
independent experiments performed in triplicate. (B) Luciferase report assay was performed on 
ECs, treated as above, 48 h after transfection with pmiR or pmiR-3’UTR c-Kit or pmiR-3’UTR p27 
Kip-1 luciferase constructs. Relative luciferase activity (%) was representative of three independent 
experiments performed in triplicate. 
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Supplemental Figure V 
 
 
Supplemental Figure V. STAT5A is a target of miR-222 in HEK293 cells. (A) qRT-PCR was 
used to measure miR-221 or miR-222 expression in HEK293 cells (left panel). Over-expression of 
miR-221 or miR-222 in HEK293 cells was obtained 48 h after transfection with miRNAs mimic 
oligonucleotides as measured by qRT-PCR (right panel). Fold expression of miRNAs was 
representative of three independent experiments performed in triplicate. (B) Luciferase activity was 
evaluated in HEK293 cells co-transfected with pre-miR negative control (neg c) or pre-miR-221 or 
pre-miR-222 precursors and pmiR or pmiR-3’UTR STAT5A or pmiR-3’UTR STAT5A mutant 
binding site (MUT). Relative luciferase activity (%) was representative of three independent 
experiments performed in triplicate. (C) Luciferase activity was evaluated in HEK293 cells 
cotransfected with pre-miR precursor oligonucleotides as above and pmiR or pmiR-3’UTR p27Kip1 
or pmiR-3’UTR cKit for 48 h. Relative luciferase activity (%) was representative of three 
independent experiments performed in triplicate. (*p<0.05, experimental vs control values). 
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Supplemental Figure VI 
 
 
Supplemental Figure VI. miR-125a-3p does not control STAT5A expression in ECs. (A) miR-
125a-3p and miR-222 expression was analyzed by qRT-PCR in quiescent or bFGF- or IL-3-treated 
ECs. Fold expression of miRNAs was representative of three independent experiments performed in 
triplicate. (B) Lysates from pre-miR negative control- (neg c), pre-miR-222- or pre-miR-125a-3p 
transfected ECs, cultured in the presence of IL-3, were analyzed by Western blots with the indicated 
antibodies. (C) Luciferase activity was evaluated in IL-3-treated ECs 48 h after co-transfection with 
the indicated pre-miRNA oligonucleotides and pmiR or pmiR-3’UTR STAT5A. Fold expression of 
miRNAs and relative luciferase activity (%) were representative of three independent experiments 
performed in triplicate. (*p<0.05, experimental vs control values). 
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Supplemental Figure VII 
 
 
 
Supplemental Figure VII. STAT5A silencing replicated miR-222 over-expressing phenotype 
in vivo. (A) Sections of Matrigel plugs, containing IL-3 or bFGF and ECs transfected with scramble 
or STAT5A siRNAs were recovered 4 days after implantation in SCID mice and subjected to 
histological analysis (10X magnification). Quantification of neo-formed vessels was expressed as 
percentage ±SD of the vessel area to the total Matrigel area. Scale bars indicate 200 µm. (B) ECs, 
recovered by CD31-positive magnetic sorting from the Matrigel plugs described above, were 
analyzed by Western Blot for STAT5A, p27 Kip1, VE-cadherin, α-SMA and β-actin expression. 
(*p<0.05, experimental vs control values). 
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Supplemental Figure VIII. 
 
 
 
Supplemental Figure VIII. miR-222 inhibits in vivo neo vessel formation by blocking EC 
proliferation. Sections of Matrigel plugs from SCID mice containing IL-3 or bFGF and ECs 
transfected with pre-miR negative control (neg c) or pre-miR-222 oligonucleotides were analyzed 
by immunofluorescence using anti CD31 or Ki67 antibodies (40X magnification). DAPI staining 
was used as nuclear marker. Scale bars indicate 20 µm. 
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Supplemental Figure IX. 
 
 
Supplemental Figure IX. ECs lining intra-plaque neo vessels express STAT5A. Representative 
samples of early and advanced human lesions double stained with anti CD31 (green) and STAT5A 
(red) antibodies. Merge (bottom panels); endothelium lining early atherosclerotic lesions expressing 
CD31 but not STAT5A are green stained; ECs lining intra-plaque vessels in advanced 
atherosclerotic lesions that co-express CD31 and STAT5A are yellow stained (10X magnification). 
Anti-mouse IgG antibody was used as negative control. Scale bars indicate 200 µm. 
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